ABSTRACT
The aim of this study was to use the World Health Organization (WHO) definition of anaemia to determine prevalence of anaemia among human immunodeficiency virus (HIV)-infected patients on the highly active antiretroviral therapy (HAART) and those that are HAART naive. Haemoglobin concentration was measured in 457 HIV patients consisting of 217 patients on HAART (86 males and 131 females) and 240 HAART naive patients (106 males and 134 females). According to WHO criteria, anaemia was defined as a haemoglobin concentration below 12g/dl in women and below 13g/dl in men. The anaemic HIV patients were further categorized according to WHO/ACTG anaemia toxicity grades. An overall anaemia prevalence of 60.61% was observed. The prevalence of anaemia was significantly higher among HAART naive patients (69.17%) than in HIV patients on HAART (51.15%) (P < 0.001). The prevalence of anaemia differ significantly (P < 0.05) between males and females of HAART naive patients with males (76.42%) having higher prevalence than females (63.43%). The WHO/ACTG categorization showed the same pattern between HIV patients on HAART and those that were HAART naive. Conclusively, the overall prevalence of anaemia was 60.61% among HIV patients. HAART naive patients have higher prevalence as well as males in this group. The WHO definition of anaemia is recommended as this will give the true prevalence of anaemia and allow for policy and interventions to address it.
Subject(s)
Anemia/epidemiology , Antiretroviral Therapy, Highly Active , HIV Infections/complications , HIV Infections/drug therapy , Adult , Anemia/complications , Female , HIV Infections/epidemiology , Humans , Male , Middle Aged , Nigeria/epidemiology , Prevalence , Sex Distribution , Urban Population , Young AdultABSTRACT
OBJECTIVE: To determine the effect of CD4 count on platelet count, prothrombin time (PT) and activated partial thromboplastin time (APTT) among HIV patients. METHOD: Blood samples were collected from 100 subjects consisting of 70 HIV treatment naive patients and 30 HIV seronegative individuals. Platelet count, CD4 count, PT and APTT were performed on the blood samples using standard techniques. RESULT: HIV-positive patients had significantly (p < 0.001) lower CD4 and platelet counts than HIV-negative subjects. Also, PT and APTT were significantly (p < 0.001) higher in HIV patients compared with their HIV negative counterparts. Among the HIV-infected patients, platelet count did not differ significantly (p > 0.05) between those with CD4 count < 200 cells//L and those with CD4 count 2 200 cells/microL. However PT and APTT were significantly (p < 0.005 and p < 0.001 respectively) higher in HIV patients with CD4 count < 200 cell/microL. Only PT significantly correlated with CD4 count (r = 0.5406, p < 0.001) and this correlation was observed only among HIV patients with CD4 count < 200 cell/pL (r = 0.6227, p < 0.001). CONCLUSION: HIV patients with CD4 count < 200 cell/pL have higher PT and APTT values; PT only correlated with CD4 count and endothelial activation is suggested as the possible mechanism for the coagulation defect.
Subject(s)
CD4 Lymphocyte Count , HIV Infections/blood , Hemostatic Disorders/virology , Partial Thromboplastin Time , Prothrombin Time , Case-Control Studies , Humans , NigeriaABSTRACT
The aim of this study was to use the World Health Organization (WHO) definition of anaemia to determine prevalence of anaemia among human immunodeficiency virus (HIV)-infected patients on the highly active antiretroviral therapy (HAART) and those that are HAART naive. Haemoglobin concentration was measured in 457 HIV patients consisting of 217 patients on HAART (86 males and 131 females) and 240 HAART naive patients (106 males and 134 females). According to WHO criteria; anaemia was defined as a haemoglobin concentration below 12g/dl in women and below 13g/dl in men. The anaemic HIV patients were further categorized according to WHO/ACTG anaemia toxicity grades. An overall anaemia prevalence of 60.61was observed. The prevalence of anaemia was significantly higher among HAART naive patients (69.17) than in HIV patients on HAART (51.15) (P 0.001). The prevalence of anaemia differ significantly (P 0.05) between males and females of HAART naive patients with males (76.42) having higher prevalence than females (63.43). The WHO/ACTG categorization showed the same pattern between HIV patients on HAART and those that were HAART naive. Conclusively; the overall prevalence of anaemia was 60.61among HIV patients. HAART naive patients have higher prevalence as well as males in this group. The WHO definition of anaemia is recommended as this will give the true prevalence of anaemia and allow for policy and interventions to address it
